Nateglinide
- Generic Name
- Nateglinide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H27NO3
- CAS Number
- 105816-04-4
- Unique Ingredient Identifier
- 41X3PWK4O2
- Background
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to mea...
- Indication
For the treatment of non-insulin dependent-diabetes mellitus in conjunction with diet and exercise.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Pilot Study to Evaluate the Effects of Nateglinide vs. Glibenclamide on Renal Hemodynamics and Albumin Excretion
- Conditions
- First Posted Date
- 2005-10-13
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT00238472
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2010-02-15
- Target Recruit Count
- 140
- Registration Number
- NCT00212290
- Locations
- 🇺🇸
VA Puget Sound Health Care System (American Lake Campus), Tacoma, Washington, United States
🇺🇸VA Puget Sound Health Care System (Seattle Campus), Seattle, Washington, United States
Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-03-13
- Lead Sponsor
- Astellas Pharma Inc
- Registration Number
- NCT00189774
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.